Please use this identifier to cite or link to this item:
Title: MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.
Authors: Peterfy, Charles
Emery, Paul
Tak, Paul P
Østergaard, Mikkel
DiCarlo, Julie
Otsa, Kati
Navarro Sarabia, Federico
Pavelka, Karel
Bagnard, Marie-Agnes
Gylvin, Lykke Hinsch
Bernasconi, Corrado
Gabriele, Annarita
Keywords: DMARDs (biologic);Inflammation;Magnetic Resonance Imaging;Rheumatoid Arthritis
metadata.dc.subject.mesh: Adult
Antirheumatic Agents
Arthritis, Rheumatoid
Cartilage, Articular
Disease Progression
Dose-Response Relationship, Drug
Double-Blind Method
Magnetic Resonance Imaging
Middle Aged
Severity of Illness Index
Treatment Outcome
Issue Date: 29-Oct-2014
Abstract: To evaluate changes in structural damage and joint inflammation assessed by MRI following rituximab treatment in a Phase 3 study of patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) who were naive to biological therapy. Patients were randomised to receive two infusions of placebo (n=63), rituximab 500 mg (n=62), or rituximab 1000 mg (n=60) intravenously on days 1 and 15. MRI scans and radiographs of the most inflamed hand and wrist were acquired at baseline, weeks 12 (MRI only), 24 and 52. The primary end point was the change in MRI erosion score from baseline at week 24. Patients treated with rituximab demonstrated significantly less progression in the mean MRI erosion score compared with those treated with placebo at weeks 24 (0.47, 0.18 and 1.60, respectively, p=0.003 and p=0.001 for the two rituximab doses vs placebo) and 52 (-0.30, 0.11 and 3.02, respectively; p This study demonstrated that rituximab significantly reduced erosion and cartilage loss at week 24 and week 52 in MTX-inadequate responder patients with active RA, suggesting that MRI is a valuable tool for assessing inflammatory and structural damage in patients with established RA receiving rituximab. NCT00578305.
metadata.dc.identifier.doi: 10.1136/annrheumdis-2014-206015
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC4717395.pdf1,09 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons